HC Wainwright

Shares of Uranium Energy Corp. (NYSE:UEC) were trading lower after the company Tuesday reported its fiscal third-quarter results. The company is likely preserving its purchased uranium inventory and waiting for stronger uranium prices, according to HC Wainwright. The Uranium Energy Analyst: Analyst...

Oklo Inc (NYSE:OKLO) reported its fourth-quarter results on Tuesday. Here are the key analyst insights: HC Wainwright analyst Sameer Joshi reiterated a Buy rating and price target of $130. Canaccord Genuity analyst George Gianarikas maintained a Buy rating, while lowering the price target from $...

Uranium Energy Corp. (NYSE:UEC) reported a significant year-on-year decline in revenues for the second quarter of fiscal 2026. Still, the company is "well-funded to support its ongoing production ramp-up," according to HC Wainwright analyst Heiko Ihle. The Uranium Energy Analyst: Ihle reiterated a...

Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Wedbush analyst Laura Chico maintained a Neutral rating, while lifting the price target from $178 to $187. HC Wainwright analyst Andrew Fein...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S (NYSE:NVO) Wegovy. • Get the market research on VNDA stock here. The...

Shares of HIVE Digital Technologies Ltd (NASDAQ:HIVE) were under pressure on Tuesday, despite an upbeat fiscal second-quarter report. Here are some key analyst takeaways: HC Wainwright analyst Mike Colonnese maintained a Buy rating and raised the price target to $10. Rosenblatt Securities...

The Food and Drug Administration agreed to accept the NDA application for the approval of Celcuity Inc's (NASDAQ:CELC) advanced breast cancer therapy, gedatolisib. The stock already prices in the prospects, according to HC Wainwright. The Celcuity Analyst: Analyst Swayampakula Ramakanth downgraded...

Contrary to the market's reaction to CoreWeave Inc's (NASDAQ:CRWV) third-quarter earnings, the results indicated "encouraging prospects," according to HC Wainwright analyst Kevin Dede. The CoreWeave Analyst: Dede maintains a Buy rating and a $180 price target. The CoreWeave Thesis: The company's...

Shares of Coinbase Global Inc. (NASDAQ:COIN) were trading higher on Friday after the company reported upbeat third-quarter results a day earlier. Here are some key analyst takeaways: JPMorgan analyst Kenneth Worthington maintained an Overweight rating, while cutting the price target from $404 to $...

Shares of Archer Aviation Inc (NYSE:ACHR) recorded gains in trading on Tuesday, despite a downbeat second-quarter report. Here are some key analyst takeaways. JPMorgan analyst Bill Peterson reiterated a Neutral rating and price target of $10. Needham analyst Chris Pierce reaffirmed a Buy rating...

CoreWeave Inc (NASDAQ:CRWV) has announced an all-stock purchase of Core Scientific Inc (NASDAQ:CORZ) in a deal valued at about $20.40 per share, or roughly $9 billion, according to HC Wainwright. The Core Scientific Analyst: Analyst Kevin Dede downgraded the rating on Core Scientific from Buy to...

Telix Pharmaceuticals Ltd (NASDAQ:TLX) is the world's most "diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company," according to HC Wainwright. The Telix Pharmaceuticals Analyst: Analyst Robert Burns initiated coverage with a Buy rating and price...

HIVE Digital Technologies Ltd (NASDAQ:HIVE) on Thursday reported its fiscal fourth-quarter results. The announcement came amid an exciting earnings season. Here are some key analyst takeaways. Rosenblatt Securities On HIVE Digital Technologies Analyst Chris Brendler maintained a Buy rating, while...

Another analyst is staying on the sidelines of CoreWeave Inc (NASDAQ:CRWV) after the rally in shares since the March IPO. The CoreWeave Analyst: H.C. Wainwright analyst Kevin Dede initiates coverage on CoreWeave with a Neutral rating with no price target. Read Also: CoreWeave’s 290% Rally...

The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency. Adrenocortical...